Oricell raises additional $45M USD to expand its CAR T-Cell therapy to United States

Oricell Therapeutics
Oricell is developing a number of CAR-T therapies and antibody candidates for solid tumors. In the Phase I trial presented at ASCO, a group of patients with treatment-resistant multiple myeloma had a 100% overall response rate and 60% stringent complete response to Oricell’s GPRC5D-directed CAR-T.

Share This Post

23rd March 2023: The preclinical and early-stage cancer cell therapies being developed by Shanghai biotech Oricell have received an additional $45 million in funding, the company announced on Tuesday.

Following a showing at ASCO last year with a GPRC5D-directed CAR-T therapy for multiple myeloma, Oricell raised a $120 million Series B in July. New investors Qiming Venture Partners and C&D Emerging Industry Equity Investment followed by existing investors RTW Investments and Qatar Investment Authority led the latest raise, which is an expansion of that round.

The biotech firm stated that newly acquired funds would be used primarily for clinical research in the US.

Oricell is working on a number of CAR-T therapies and solid tumour antibody candidates. A group of patients with treatment-resistant multiple myeloma responded to Oricell’s GPRC5D-directed CAR-T with a 100% overall response rate and 60% stringent complete response in the Phase I trial that was presented at ASCO.

You may like to read: CAR T-Cell therapy in China

In particular, Oricell highlighted a group of five patients who had already received BCMA CAR-T therapy. According to the company, one partial response, two “very good partial responses,” and two stringent complete responses were all received. And with a median follow-up ranging from 35 to 281 days, all were progression-free at the cutoff date at ASCO.

According to Oricell, which is currently in the IND-enabling stage, it hopes to extend the trial for its GPRC5D-directed CAR-T therapy to the US.

In addition, Oricell has a GPC3-directed CAR-T cell therapy called Ori-C101, which it’s studying in advanced hepatocellular carcinoma.

CAR T-Cell therapy is among the breakthrough treatments for certain types of blood cancers. There are more than 750 ongoing clinical trials in CAR T-Cell therapy in China at present. Patients who wish to enroll can contact the CancerFax patient helpline on WhatsApp +91 96 1588 1588 or email to info@cancerfax.com.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer
Colon cancer

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

The FDA has granted accelerated approval to Adagrasib combined with Cetuximab for treating KRAS G12C-mutated colorectal cancer. This approval is based on promising clinical trial results showing enhanced efficacy of the drug duo. Adagrasib, a KRAS inhibitor, and Cetuximab, an EGFR inhibitor, together target the cancer more effectively, offering new hope for patients with this specific genetic mutation, aiming to improve survival rates and treatment outcomes.

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma
Endometrial cancer

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma

The USFDA has approved Pembrolizumab combined with chemotherapy for treating primary advanced or recurrent endometrial carcinoma. This approval is based on clinical trial data showing significant improvements in patient outcomes. Pembrolizumab, an immune checkpoint inhibitor, works by enhancing the body’s immune response against cancer cells. This combination therapy offers a new and promising treatment option for patients facing this challenging and often aggressive cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy